Related Experiment Video
Updated: Jun 4, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
[Management of cardiac arrhythmias during pregnancy]
S Fennira1, M H Khaldi, M A Rejeb
1Service de cardiologie, hôpital Habib Thameur, faculté de médecine de Tunis, Tunisie. fennira2@yahoo.fr
Introduction:
Pregnancy can precipitate or exacerbate cardiac arrhythmias. Management of those arrhythmias is not very different from that in non-pregnant women.
Objective:
In this review we tried to specify factors which favour arrhythmias in pregnant women and to show their specific management.
Methods:
We carried out a search through PubMed using as keywords: pregnancy, cardiac arrhythmias, antiarrhythmics.
Results:
Hemodynamic perturbations, direct electrophysiological effects of hormones and underlying heart disease are potential factors that can promote arrhythmias in pregnancy. Usually, no drug therapy is needed for the management of supraventricular or ventricular premature beats but potential promoting factors should be eliminated. In paroxysmal supraventricular tachycardia, vagal maneuvers should be tried firstly. Adenosine could be used if vagal maneuvers are ineffective. In pregnant women with atrial fibrillation, the goal of treatment is the conversion to sinus rhythm or the control of ventricular rate. Ventricular arrhythmias are usually uncommon during pregnancy and often occur in the absence of structural heart disease and are responsive to drug therapy. Symptomatic bradycardia rarely complicates pregnancy and its management does not differ from that in non-pregnant women.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmias VII: Nursing Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Mechanism of Cardiac Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
